Join a Journey that Brings New Hope
to No-Option Patients

The purpose of this clinical trial is to evaluate the efficacy and safety of our innovative cell-therapy solution for patients with critical limb ischemia (CLI) and chronic limb-threatening ischemia (CLTI), with the end goal being 12 months amputation-free survival.

BGC101 phase 2 clinical trial is considered for the FDA’s fast track, and therefore requires xxx patients to be enrolled.

If you’re interested in participating in this clinical trial, speak to your doctor or contact the trial coordinators for more information on how to apply.

The three steps of the cell-therapy solution include a simple blood draw, a rapid processing stage in which the patient’s own stem cells are re-trained by the immune system cells – and shortly after administered directly to the patient via injection.

The treatment process will involve only two visits to the clinic- one for the simple blood draw and one shortly after, for the rapid and simple re-injection of the “re-trained” blood cells.

The potential benefits of this cell-therapy solution include improved blood flow to the affected limb, reduced pain, increased mobility, and an overall better quality of life for patients with CLI and CLTI.

Like all clinical trials, this study comes with risks, such as the risk of infection or injury from the blood draw or injection sites. Your doctor will inform you of all the potential risk before enrolling in the study.

Once the study is over, research data is analyzed to assess the safety and efficacy of the cell-therapy solution. The results of the study may inform whether or not the cell-therapy solution becomes available to patients as an accessible and approved treatment.

Yes, you can withdraw from the clinical trial at any point without any obligation or impact on your medical care. Your doctor will discuss options before you make the decision to withdraw.